Delivering at the companys 18th annual general meeting here on Monday, its Chairman Dr K Anji Reddy said, I would like to re-emphasise the breadth and width of the research pipeline that has built over the years, the efforts will not only remain committed to sustain the strong pipeline but also advance more molecules through various clinical phases of development. Claiming that the risks are inherent in the drug discovery process, Dr Anji Reddy felt that the risks could be managed intelligently by balancing the financial risk with return and control over the development process.
The company has claimed to mitigate such risks while continue the R&D efforts, he said. Announcing that Dr Reddys has a strong pipeline of products at various stages of pre-clinical and clinical development, Dr Anji Reddy said that another molecule DRF-2595 (Balaglitazone) outlicensed to Novo Nordisk, is undergoing Phase II trails for its potential benefits in diabetic-dyslipidemic patients.
While DRF 1042, an orally active topoisomerase inhibitor, an anti-cancer molecule, has completed phase I in India and plans to initiate multi-center phase II trials in the country, DRF 1644, another topoisomerase inhibitor for intravenous use, is expected to commence phase I trails soon, Dr Anji Reddy said.
The scientist-turned-industrialist reveled that the Dr Reddys research outfit has so far short-listed a several lead candidates in the area of anti-bacterials and in contact with potential partners for co-development of promising drug candidates in the area of restenosis and transplant vascuolopathy.
GV Prasad, vice-president and CEO of Dr Reddys said that, Aurigene Discovery Technologies Ltd, a subsidiary aiming to offer discovery services to other companies, is expected to commence operations by the end of the third quarter of the current fiscal. Explaining the future strategy, Mr Prasad said that the company is proposed to focus on the branded specialty products and the US generics as growth engines to transform Dr Reddys into global pharma player. Also plans to create own sales and marketing infrastructure in the US and certain other key markets, he added.
About the US generic pipeline, Mr Prasad said that the company has filed 14 ANDAs and plans to file 10 to 12 ANDAs in the next six months, which aggregating brand sales of $13 billion. The company has already launched two products in the UK market through its acquisition, BMS Meridian, he added.